Michael A. Mussallem is chairman and chief executive officer of Edwards Lifesciences Corporation, the world’s leader in heart valve technologies. Headquartered in Irvine, Calif., Edwards leverages its research, design, development and marketing expertise to address specific cardiovascular opportunities, including heart valve disease, vascular disease and critical care technologies.
Mussallem has headed Edwards Lifesciences since it was spun off from Baxter International Inc. and began operating as an independent, publicly traded company (NYSE:EW) in April 2000. Previously, he was responsible for the worldwide operations of both Baxter’s CardioVascular business, which he had headed since 1995, and its Biopharmaceuticals business, which he had been appointed to lead in 1998.
Mussallem joined Baxter in 1979 and progressed through a variety of increasingly responsible positions in manufacturing, engineering and product development. He was named president of Baxter’s Critical Care Division in 1993, and group vice president of Baxter’s Surgical Group in 1994. From 1996 through 1998, he chaired Baxter’s Asia-Pacific Board, which coordinated all of Baxter’s regional initiatives. Previously, he worked for Union Carbide.
Mussallem is chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed), and serves as a member of the board for Advanced Medical Optics, Inc. He is also on the boards and executive committees of the California Healthcare Institute and OCTANe, and is a trustee of the University of California, Irvine Foundation. He received a bachelor’s degree in chemical engineering in 1974 and an honorary doctorate in 1999 from the Rose-Hulman Institute of Technology in Terre Haute, Indiana.